191 related articles for article (PubMed ID: 32433789)
41. Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model.
Kansara R; Villa D; Gerrie AS; Klasa R; Shenkier T; Scott DW; Slack GW; Gascoyne RD; Connors JM; Sehn LH; Savage KJ
Br J Haematol; 2017 Nov; 179(3):508-510. PubMed ID: 27443424
[No Abstract] [Full Text] [Related]
42. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.
Villa D; Connors JM; Shenkier TN; Gascoyne RD; Sehn LH; Savage KJ
Ann Oncol; 2010 May; 21(5):1046-52. PubMed ID: 19861575
[TBL] [Abstract][Full Text] [Related]
43. Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis--A Systematic Review of Prospective Studies.
Ghose A; Elias HK; Guha G; Yellu M; Kundu R; Latif T
Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):451-7. PubMed ID: 25816933
[TBL] [Abstract][Full Text] [Related]
44. [Central nervous system relapse in diffuse large B cell lymphoma: Risk factors].
Sancho JM; Ribera JM;
Med Clin (Barc); 2016 Jan; 146(2):74-80. PubMed ID: 25817451
[TBL] [Abstract][Full Text] [Related]
45. Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.
Thanarajasingam G; Maurer MJ; Farooq U; Johnston PB; Thompson CA; Bennani NN; Ansell SM; Porrata LF; Macon WR; Syrbu SI; Cerhan JR; Habermann TM; Link BK; Witzig TE; Nowakowski GS
Br J Haematol; 2018 Oct; 183(1):149-152. PubMed ID: 28961306
[No Abstract] [Full Text] [Related]
46. Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
Wight JC; Yue M; Keane C; Johnston A; Linton K; Chin C; Wai SH; Talaulikar D; Gasiorowski R; Cheah CY; Gregory GP; Dickinson M; Minson A; Coombes C; Ku M; Lam S; Hawkes EA
Br J Haematol; 2019 Oct; 187(2):174-184. PubMed ID: 31236941
[TBL] [Abstract][Full Text] [Related]
47. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment.
van Besien K; Gisselbrecht C; Pfreundschuh M; Zucca E
Leuk Lymphoma; 2008; 49 Suppl 1():52-8. PubMed ID: 18821433
[TBL] [Abstract][Full Text] [Related]
48. [Central nervous system involvement in diffuse large B-cell lymphoma: prevention and treatment].
Zhou D; Zhang W
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):284-5. PubMed ID: 24759011
[No Abstract] [Full Text] [Related]
49. Central nervous system relapse in patients with diffuse large B-cell lymphoma: analysis of incidence and prognostic factors.
Uni M; Kagoya Y; Nannya Y; Nakamura F; Kurokawa M
Leuk Lymphoma; 2015 Jun; 56(6):1869-71. PubMed ID: 25267182
[No Abstract] [Full Text] [Related]
50. Central nervous system relapse in patients with diffuse large B cell lymphoma: analysis of the risk factors and proposal of a new prognostic model.
Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
Ann Hematol; 2016 Oct; 95(10):1661-9. PubMed ID: 27370993
[TBL] [Abstract][Full Text] [Related]
51. Central Nervous System Lymphoma.
Chukwueke UN; Nayak L
Hematol Oncol Clin North Am; 2019 Aug; 33(4):597-611. PubMed ID: 31229157
[TBL] [Abstract][Full Text] [Related]
52. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement.
Lee KW; Yi J; Choi IS; Kim JH; Bang SM; Kim DW; Im SA; Kim TY; Yoon SS; Lee JS; Bang YJ; Park S; Kim BK; Cho HI; Heo DS
Ann Hematol; 2009 Sep; 88(9):829-38. PubMed ID: 19172274
[TBL] [Abstract][Full Text] [Related]
53. Brief chemotherapy, involved field radiation therapy, and central nervous system prophylaxis for paranasal sinus lymphoma.
Cooper DL; Ginsberg SS
Cancer; 1992 Jun; 69(12):2888-93. PubMed ID: 1375527
[TBL] [Abstract][Full Text] [Related]
54. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
O'Rourke K; Morris K; Kennedy GA
Cancer; 2011 Jun; 117(11):2579-80; author reply 2580-1. PubMed ID: 24048807
[No Abstract] [Full Text] [Related]
55. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology.
McMillan A; Ardeshna KM; Cwynarski K; Lyttelton M; McKay P; Montoto S;
Br J Haematol; 2013 Oct; 163(2):168-81. PubMed ID: 24033102
[TBL] [Abstract][Full Text] [Related]
56. CNS prophylaxis in lymphoma: who to target and what therapy to use.
Hill QA; Owen RG
Blood Rev; 2006 Nov; 20(6):319-32. PubMed ID: 16884838
[TBL] [Abstract][Full Text] [Related]
57. Optimizing initial therapy in DLBCL.
Thieblemont C; Bernard S; Meignan M; Molina T
Best Pract Res Clin Haematol; 2018 Sep; 31(3):199-208. PubMed ID: 30213389
[TBL] [Abstract][Full Text] [Related]
58. Intrathecal Central Nervous System Prophylaxis in Patients With Diffuse Large B-cell Lymphoma at an Academic Healthcare System.
Hall KH; Valla K; Flowers CR; Cohen JB
Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):89-94. PubMed ID: 30528416
[TBL] [Abstract][Full Text] [Related]
59. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
González-Barca E; Canales M; Salar A; Ferreiro-Martínez JJ; Ferrer-Bordes S; García-Marco JA; Sánchez-Blanco JJ; García-Frade J; Peñalver J; Bello-López JL; Sancho JM; Caballero D;
Ann Hematol; 2016 May; 95(6):893-9. PubMed ID: 27025508
[TBL] [Abstract][Full Text] [Related]
60. The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis.
Tomita N; Yokoyama M; Yamamoto W; Watanabe R; Shimazu Y; Masaki Y; Tsunoda S; Hashimoto C; Murayama K; Yano T; Okamoto R; Kikuchi A; Tamura K; Sato K; Sunami K; Shibayama H; Takimoto R; Ohshima R; Takahashi H; Moriuchi Y; Kinoshita T; Yamamoto M; Numata A; Nakajima H; Miura I; Takeuchi K
Leuk Lymphoma; 2018 Jan; 59(1):97-104. PubMed ID: 28593796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
